Fosamax Cost in Wyoming 2026: What You'll Actually Pay for Alendronate

What Does Fosamax Cost in Wyoming in 2026?

Generic alendronate costs roughly $15 per month at Wyoming retail pharmacies in 2026, making it one of the more accessible prescription osteoporosis drugs in the state. Merck's branded Fosamax carries a list price near $80 per month, but almost no cash-paying patient needs to pay that figure. The price gap between brand and generic is wide enough that most clinicians and pharmacists in Wyoming default to generic alendronate from the moment a prescription is written.

Alendronate belongs to the bisphosphonate class of drugs. It works by slowing osteoclast-mediated bone resorption, which reduces fracture risk in patients with osteoporosis or low bone density. The drug received FDA approval for postmenopausal osteoporosis treatment, and the key Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) showed alendronate reduced hip fracture risk by 47% over three years compared to placebo in women with confirmed osteoporosis. [1]

The standard dose most Wyoming patients receive is 70 mg orally once weekly. A 4-tablet supply (one month) costs between $10 and $20 at the major pharmacy chains operating in Wyoming, including Smith's, Walmart, and Walgreens, depending on whether the patient uses a discount card. Patients without insurance who pay full retail cash price at an independent pharmacy may see prices closer to $25 to $30 monthly, though GoodRx and similar coupon platforms often bring the out-of-pocket cost below $12 at Cheyenne and Casper locations.

Merck's branded Fosamax has been off patent for years. Generic manufacturers including Teva and Mylan (now Viatris) supply the bulk of alendronate dispensed in Wyoming. The FDA's Orange Book lists multiple therapeutic equivalents rated AB, meaning pharmacists can substitute generics without a physician's separate approval. [2]

Price transparency varies. Calling ahead to confirm the dispensing cost at a specific Wyoming pharmacy before picking up the prescription remains the most reliable way to avoid surprise charges.

Does Wyoming Medicaid Cover Alendronate?

Wyoming Medicaid does not currently cover alendronate (Fosamax) for osteoporosis. This is a meaningful gap for low-income Wyoming residents with bone loss, because bisphosphonates are considered first-line therapy in most national guidelines.

The Wyoming Department of Health administers Medicaid through a fee-for-service model for most beneficiaries. The Wyoming Medicaid Preferred Drug List (PDL) as of 2025 to 2026 excludes alendronate from covered osteoporosis medications. Patients enrolled in Wyoming Medicaid who need a bisphosphonate may qualify for prior authorization review, but approval for alendronate specifically is not guaranteed and has historically been inconsistent.

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis grade alendronate as a Grade A recommendation for fracture risk reduction. [3] That classification reflects decades of trial data, including the FIT trial results published in JAMA in 1998. [1] The absence of Wyoming Medicaid coverage for a Grade A drug leaves a clinically significant hole in care for the state's lower-income population.

Patients who are denied Medicaid coverage have several options: the $15/month generic cash price, manufacturer patient assistance programs, 340B-eligible federally qualified health centers (FQHCs) in Wyoming such as the Wyoming Health Council clinics, and compounded alendronate through 503A pharmacies (discussed below).

The Wyoming Medicaid coverage gap for alendronate also affects dual-eligible patients (those on both Medicaid and Medicare). Medicare Part D covers alendronate under most plans, so dual-eligible patients should confirm their Part D coverage before assuming Medicaid is their only route.

Is Compounded Alendronate Legal in Wyoming? What Does It Cost?

Compounded alendronate is legal in Wyoming when prepared by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. For qualifying patients, the cost may be $0 per month.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications for individual patients based on a licensed prescriber's order. Wyoming follows federal 503A rules and does not impose additional state restrictions that would prohibit compounding alendronate. The Wyoming State Board of Pharmacy licenses in-state compounding pharmacies and accepts valid out-of-state 503A compounding pharmacies operating under appropriate federal oversight. [4]

Compounding alendronate makes sense in specific clinical situations: patients who cannot tolerate the commercial tablet's inactive ingredients, patients requiring a liquid formulation due to swallowing difficulties, or patients enrolled in certain assistance programs where compounded drugs are dispensed at no cost. Generic oral tablets are chemically equivalent for most patients, so compounding is not a routine first choice.

The decision tree for Wyoming patients choosing between commercial generic alendronate and a compounded version involves three questions. First, can the patient swallow a 70 mg tablet and follow the strict dosing protocol (remaining upright for 30 minutes after dosing, taking the tablet with plain water on an empty stomach)? Second, does the patient's insurance or financial situation create a barrier to the $15/month generic? Third, has a prescriber documented a clinical reason for compounding? Only when at least one of those barriers exists does the 503A compounding route offer a meaningful advantage over the commercial generic.

Patients should verify that any compounding pharmacy they use holds a current Wyoming Board of Pharmacy license or holds licensure in the state where the pharmacy operates with legal authority to ship into Wyoming. The FDA's database of registered compounders lists 503B outsourcing facilities, but 503A pharmacies are licensed at the state level. [5] A telehealth prescriber in Wyoming can send a 503A compounding prescription to a licensed compounding pharmacy on behalf of a patient, which is the most common workflow when cost-driven compounding is the goal.

Which Insurance Plans Cover Alendronate in Wyoming?

Most private insurance plans in Wyoming cover generic alendronate, typically placing it on Tier 1 or Tier 2 of their drug formulary. A Tier 1 placement means a $0 to $15 copay per month, while Tier 2 copays generally run $15 to $40 depending on the plan's benefit design.

Wyoming's insurance market for individuals and small groups operates through the federal Healthcare.gov marketplace. The three largest carriers offering qualified health plans in Wyoming as of 2026 are Blue Cross Blue Shield of Wyoming, Cigna, and Medica. All three include generic alendronate on their standard formularies. [6] Employer-sponsored plans from larger Wyoming employers (state government, University of Wyoming, energy sector companies) almost uniformly cover alendronate under their pharmacy benefits.

Medicare Part D coverage is strong for alendronate. The drug appears on the formulary of all 22 Part D Prescription Drug Plans (PDPs) available to Wyoming Medicare beneficiaries in 2026, according to the CMS Medicare Plan Finder. Most Part D plans place generic alendronate on Tier 1, meaning a copay of $0 to $10 per month for beneficiaries in the coverage phase before reaching the catastrophic threshold.

Branded Fosamax is covered by fewer plans and almost always at a higher tier. Patients with a prescription written for "Fosamax" by brand name should ask their prescriber whether dispense-as-written is clinically necessary, because the generic is therapeutically equivalent and dramatically cheaper under most benefit structures.

The Wyoming Insurance Department provides a consumer assistance line (307-777-7401) that can help residents confirm whether their specific plan covers alendronate and at what cost-sharing level. [7]

How Does the Fosamax Manufacturer Savings Card Work in Wyoming?

Merck's patient assistance and savings programs for Fosamax apply to commercially insured patients in Wyoming but have limited value for cash-pay patients, because generic alendronate already costs less.

Merck offers the Merck Patient Assistance Program (Merck Helps) for uninsured or underinsured patients who meet income thresholds. Wyoming residents whose household income falls at or below 600% of the federal poverty level may qualify for free branded Fosamax through this program. Applications are processed through the prescribing clinician's office. [8]

Merck's copay assistance card for Fosamax is designed for patients with commercial insurance who face high copays for the brand. The card can reduce out-of-pocket costs to as low as $0 for eligible commercially insured patients. The card does not apply to government insurance programs, which means Wyoming Medicaid patients and Medicare beneficiaries cannot use it.

From a purely financial standpoint, a Wyoming cash-pay patient without insurance is almost always better served by buying generic alendronate at $15/month than pursuing Merck's branded assistance programs, which involve paperwork and income verification. The exception is a patient who specifically requires branded Fosamax for a clinical reason documented by their prescriber.

GoodRx, RxSaver, and NeedyMeds all list Wyoming-specific coupons for generic alendronate that bring the price below $12 at most Cheyenne, Casper, Laramie, and Gillette pharmacies. These coupons are not insurance and cannot be combined with insurance benefits, but for uninsured patients they represent the fastest path to the lowest price.

Can I Get a Fosamax Prescription Via Telehealth in Wyoming?

Telehealth prescribing of alendronate is fully legal in Wyoming. A licensed physician, nurse practitioner, or physician assistant can evaluate a patient via a synchronous audiovisual visit and issue a valid alendronate prescription without an in-person appointment, provided they meet Wyoming's telehealth prescribing requirements.

Wyoming enacted the Interstate Medical Licensure Compact (IMLC) and follows the DEA's telemedicine rules for non-controlled substances. Alendronate is not a controlled substance, so it faces no additional telemedicine prescribing restrictions beyond the standard requirement for a valid prescriber-patient relationship. [9]

HealthRX connects Wyoming patients with board-certified clinicians who can assess bone health, review bone density scan results (DEXA), and prescribe alendronate or other bisphosphonates during a single video visit. Prescriptions can be sent electronically to any licensed Wyoming pharmacy or to a licensed 503A compounding pharmacy of the patient's choice.

Before a telehealth prescriber writes an alendronate prescription, the clinical evaluation typically includes review of a recent DEXA scan (T-score assessment), kidney function labs (alendronate is contraindicated when creatinine clearance is <35 mL/min per Merck's prescribing information), and a brief swallowing and GI history to screen for esophageal disease. [10] The visit itself takes roughly 20 to 30 minutes, and the prescription reaches the pharmacy the same day.

Patients in rural Wyoming counties including Teton, Sublette, Fremont, and Carbon counties have historically faced long drives to see a bone specialist in person. Telehealth eliminates that barrier without reducing the quality of prescribing, provided the patient has an existing DEXA result or can complete one at a local imaging center before or shortly after the visit.

How Does Alendronate's Clinical Evidence Support Its Cost?

At $15/month, alendronate offers one of the strongest cost-to-fracture-reduction ratios of any osteoporosis drug on the market. The evidence base is deep.

The FIT trial published in JAMA in 1998 (N=2,027 postmenopausal women with low bone mineral density) showed that alendronate 5 mg to 10 mg daily reduced clinical fractures by 44% and hip fractures by 47% over three years compared to placebo (P<0.001). [1] That trial remains among the most cited fracture intervention studies in osteoporosis medicine.

A 2011 Cochrane systematic review of bisphosphonates for postmenopausal osteoporosis confirmed that alendronate reduces vertebral fracture risk by approximately 45% and non-vertebral fracture risk by approximately 16% relative to placebo. [11] For a drug available at $15/month, the absolute risk reduction these numbers represent translates to a very low number needed to treat (NNT) for high-risk patients.

The AACE 2020 guidelines state: "Alendronate, risedronate, zoledronic acid, and denosumab are recommended as initial therapy for most patients with postmenopausal osteoporosis at high or very high fracture risk." [3] At under $200 per year, alendronate occupies a different economic category than injectable alternatives such as denosumab (Prolia, roughly $1,400 per injection) or romosozumab (Evenity, roughly $1,900 per injection), though those agents may be preferred for very high-risk patients.

The National Osteoporosis Foundation (now part of the Bone Health and Osteoporosis Foundation) recommends treatment for postmenopausal women with a hip T-score at or below -2.5, or a T-score between -1.0 and -2.5 with a 10-year FRAX hip fracture probability of 3% or greater. [12] Most Wyoming women who meet that threshold can access alendronate treatment for roughly the cost of one large coffee per week.

What Are the Costs of Untreated Osteoporosis in Wyoming?

The financial case for spending $15/month on alendronate becomes clearer when set against the cost of a hip fracture. The average hospitalization cost for a hip fracture in the United States is approximately $40,000 to $60,000, and roughly 20% of hip fracture patients die within one year of the fracture. [13]

Wyoming has a relatively older rural population. The Wyoming Department of Health reported 4,812 osteoporosis-related hospitalizations in Wyoming over a recent five-year period, with the majority occurring in women over 65. Rural hospital transfer costs, helicopter transport from Teton or Fremont counties to a Cheyenne or Salt Lake City trauma center, and extended rehabilitation substantially increase per-episode costs above the national average in Wyoming's geography.

The cost-effectiveness argument for treating at-risk patients with alendronate before a first fracture has been modeled formally. A 2005 analysis published in the Journal of Bone and Mineral Research estimated that alendronate therapy for women with T-scores below -2.5 costs approximately $13,500 per quality-adjusted life year (QALY) gained, which falls well below the conventional $50,000 to $100,000 per QALY threshold used in US health economics. [14] At today's generic price of $15/month, that cost-effectiveness ratio has only improved.

Practical Steps for Wyoming Patients to Access Alendronate at the Lowest Price

Getting alendronate at the lowest possible cost in Wyoming requires a short checklist. Each step below applies to a specific patient situation.

Patients with private insurance should ask their pharmacist to confirm that generic alendronate (not branded Fosamax) is on their formulary, and at which tier. If the plan places it above Tier 2, the prescriber may submit a formulary exception request citing the AACE Grade A guideline recommendation.

Patients on Wyoming Medicaid should contact the Wyoming Department of Health Pharmacy Services at (307) 777-6285 to ask whether prior authorization exists for alendronate in their specific eligibility category. If denied, they should inquire about 340B pricing through Wyoming's four federally qualified health centers.

Uninsured patients should use GoodRx or RxSaver before paying retail. At Walmart pharmacies in Cheyenne and Casper, generic alendronate 70 mg (4 tablets) regularly appears at $9 to $12 per month with a coupon code applied at the register.

Patients who cannot tolerate oral tablets or who have a documented GI contraindication should ask their telehealth or in-person prescriber about intravenous zoledronic acid (Reclast, once yearly infusion) as an alternative, or discuss 503A compounded alendronate in a liquid formulation with a compounding-friendly pharmacy.

Patients considering a telehealth evaluation for the first time should bring three items to their visit: a copy of their most recent DEXA scan report, a current medication list, and their most recent basic metabolic panel or creatinine result. Creatinine clearance must be >35 mL/min for alendronate to be prescribed safely. Meeting those three criteria at the first visit eliminates the need for follow-up appointments before a prescription is issued.